# Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a

> **NCT01514370** · PHASE2 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 80 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** IFN beta 1a 44 mcg TIW
- **DRUG:** Curcumin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01514370
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04-30
- **Primary completion:** 2016-03-31
- **Final completion:** 2016-03-31
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2019-01-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01514370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01514370, "Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01514370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*